179688-52-9

Basic information

• Product Name: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one
• Synonyms: 6-HYDROXY-7-METHOXY-3,4-DIHYDROQUINAZOLIN-4-ONE;6-Hydroxy-7-Methoxyquinazoline-4-One;6-hydydroxy-7-methoxyquinazoline-4-one;6-Hydroxy-7-methoxy-3H-quinazolin-4-one;7-METHOXYQUINAZOLINE-4,6-DIOL;4(3H)-Quinazolinone, 6-hydroxy-7-Methoxy-;Gefitinib interMediate III;6-Hydroxy-7-Methoxyquinazolin-4(1H)-one
• CAS NO: 179688-52-9
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.17
• EINECS: 1308068-626-2
• Product Categories: API intermediates
• Mol File: 179688-52-9.mol
• Article Data: 54

Chemical Properties

• Melting Point: 293 °C
• Boiling Point: 503.319 °C at 760 mmHg
• Flash Point: 258.198 °C
• Appearance: /
• Density: 1.478 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.659
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.39±0.20(Predicted)
• CAS DataBase Reference: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(179688-52-9)
• EPA Substance Registry System: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(179688-52-9)

Safety Data

• Hazardous Substances Data: 179688-52-9(Hazardous Substances Data)

Usage

Description

6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one is a white powder chemical compound that serves as a key reactant in the synthesis of various bioactive molecules with potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one is used as a reactant for the preparation of 4-anilinoquinazoline derivatives, which have demonstrated antitumor activities. These derivatives are valuable in the development of anticancer drugs targeting various types of cancer.
Used in Medicinal Chemistry Research:
6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one is also utilized as a reactant in the synthetic preparation of 2-arylbenzothiazoles, which are known as kinase inhibitors. Kinase inhibitors are important in the regulation of cellular processes and have potential applications in the treatment of various diseases, including cancer and inflammatory conditions.

InChI:InChI=1/C9H8N2O3/c1-14-8-3-6-5(2-7(8)12)9(13)11-4-10-6/h2-4,12H,1H3,(H,10,11,13)

Upstream product

• 50413-44-0 methyl 2-amino-5-hydroxy-4-methoxybenzoate 
• 3473-63-0 formamidine acetic acid 
• 31839-21-1 2-amino-5-hydroxy-4-methoxybenzoic acid 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 463-52-5 formamidine 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 290-87-9 1,3,5-Triazine 
• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 621-59-0 isovanillin 
• 64-18-6 formic acid 
• 77287-34-4 formamide 
• 20357-25-9 6-nitroveratraldehyde 
• 120-14-9 3,4-dimethoxy-benzaldehyde 

Downstream Products

• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 295330-64-2 4-[(3-bromo-phenyl)amino]-6-methylcarbonyloxy-7-methoxy-quinazoline 
• 1389355-13-8 C₁₇H₁₄ClF₂N₃O₂ 
• 1389355-17-2 C₁₇H₁₅BrFN₃O₂ 
• 1389355-28-5 N-(3-chloro-4-fluorophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 1389355-29-6 N-(3-ethynylphenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 1389355-33-2 N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 295330-61-9 4-[(3-bromophenyl)amino]-6-hydroxy-7-methoxyquinazoline 
• 808762-62-1 4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate 
• 808762-63-2 4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol 
• 1437310-79-6 N-(4-bromo-2-fluorophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine 
• 1438072-35-5 N-(4-bromo-2-fluorophenyl)-7-methoxy-6-(3-(tetrahydro-2H-[1,4]dioxino[2,3-c]pyrrol-6(3H)-yl)propoxy)quinazolin-4-amine 
• 1438080-43-3 tert-butyl 5-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438072-41-3 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 

Relevant articles and documents

Studies leading to the identification of ZD1839 (Iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.

Preparation method of high-purity gefitinib key intermediate

The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of a high-purity gefitinib key intermediate 6-hydroxy-7-methoxy-3H-quinazoline-4-ketone. The synthesis method is simple to operate, the yield is high, t

INHIBITORS OF MUTANT EGFR FAMILY TYROSINE-KINASES

An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.